Chugai Pharmaceutical Co., Ltd. (4519.T) JPX

6,979.00

+152(+2.23%)

Updated at October 03 03:30PM

Currency In JPY

Chugai Pharmaceutical Co., Ltd.

Address

Nihonbashi Mitsui Tower

Tokyo, 103-8324

Japan

Phone

81 3 3281 6611

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

5026

First IPO Date

January 04, 2000

Key Executives

NameTitlePayYear Born
Dr. Osamu OkudaPresident, Chief Executive Officer & Chairman282M1963
Mr. Iwaaki TaniguchiExecutive Vice President, Head of Finance Supervisory Division, Chief Financial Officer & Director01966
Dr. Tomoyuki Igawa Ph.D.Vice President & Head of Research Division0N/A
Mr. Shinji HidakaExecutive Vice President0N/A
Mr. Tetsuya YamaguchiExecutive Vice President0N/A
Mr. Yoshiyuki YanoExecutive Vice President0N/A
Mr. Kosuke IijimaHead of PHC Solution Department0N/A
Toshiya SasaiExecutive of Investor Relations Group & Corporate Communications Department0N/A
Junichi TakanoHead of Marketing & Sales Division0N/A
Dr. Kaori OuchiExecutive Vice President0N/A

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.